Thursday, September 28, 2023
10:18 AM EST – Medicenna Therapeutics Corp. : Will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held from October 1 – 4, in Toronto. Medicenna Therapeutics Corp. (T.MDNA) shares were unchanged at 0.38.
Stocks in Play: Medicenna Therapeutics Corp., Thu, 28 Sep 2023 10:27:06 EST